As of June 2026, according to Innoviva's latest financial report, the company's current EPS (TTM) is $7.2. In 2025, the company recorded an earnings per share (EPS) of $4.02, which represents an increase compared to its EPS of $0.37 in 2024. Innoviva's earnings per share for the quarterly report ending on Mar 31, 2026 was $2.52.
The annual EPS in 2025 was $4.02, an increase of 986.5% from $0.37 in 2024. For the quarter ending Mar 31, 2026, the EPS was $2.52, showing a 440.5% increase from the same quarter last year. The trailing twelve months (TTM) EPS as of March 2026 is $7.2. In 2024, the annual EPS was $0.37, showing a decrease of 86.5% from 2023.
Over the last 12 months, Innoviva has registered an EPS growth of 440.5% (YoY, quarterly). Looking at a longer timeframe, the company recorded an average EPS growth rate of 9.4% per year over the past 3 years. Over the last 5 years, the company had an average EPS growth rate of 12.7%.
| Stock name | Price to Earnings | EPS grwoth 1Y | EPS grwoth 3Y | EPS grwoth 5Y |
|---|---|---|---|---|
| INVA Innoviva Inc | 3.08 | 986.5% | 9.4% | 12.7% |
| OPK Opko Health Inc | N/A | -275% | N/A | N/A |
| ORGO Organogenesis Holdings Inc | N/A | 1,700% | 10.1% | 0% |
All data is based on quarterly TTM periods, unless otherwise specified.